Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0348321 (Haemophilus)
15,372 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The reasons for combining trimethoprim (TMP) with sulfonamides (SUL) are still mainly theoretical but are supported by results from experimental infections and treatment of specific pathogens in humans, such as Branhamella catarrhalis, Neisseria gonorrhoeae, Brucella, Nocardia asteroides and perhaps Bordetella pertussis and Chlamydia trachomatis. Addition of SUL to TMP confers a therapeutic advantage also in patients with complicated urinary tract infection but probably not in young women with acute cystitis. Conditions that may enable TMP-SUL synergy in vivo can be expected to occur only in occasional cases of infection due to staphylococci, streptococci, Haemophilus or enteric bacteria. This fact together with ethical problems and availability of alternative therapies make further evaluations of the clinical significance of the SUL component of TMP-SUL very difficult. Although the use of TMP alone has shown promise in exacerbations of chronic bronchitis the role of the SUL component in TMP-SUL treatment of infections outside the urinary tract remains to be defined in comparative clinical trials.
...
PMID:Significance of the sulfonamide component for the clinical efficacy of trimethoprim-sulfonamide combinations. 351 51

The commercially available API ZYM microbiological identification system was evaluated for the rapid identification of Haemophilus somnus. Eighty-seven isolates of the organism had API ZYM profiles which were characteristic. The API ZYM profiles demonstrate clear differences between H. somnus and other genera but suggest a close association to three related organisms. Enzyme activity of H. somnus isolates were similar to organisms identified as Histophilus ovis, Haemophilus agni and strains UQV of Actinobacillus actinoides and Actinobacillus seminis but was clearly different from isolates of Pasteurella haemolytica, Pasteurella multocida, Bordetella bronchiseptica and group EF4. The API ZYM system allowed more rapid identification of H. somnus than conventional biochemical tests and may be a useful adjunct to conventional methods used for identification of H. somnus isolates. The test did not reveal obvious differences between isolates from various anatomic locations.
...
PMID:An evaluation of the API ZYM system as a means of identifying Haemophilus somnus and related taxa. 353 Apr 16

805 clinical isolates were investigated for their in vitro sensitivity against Ro 15-8074 and Ro 19-5247 in comparison to cefaclor and cefalexin in a serial dilution test on solid medium. Ro 19-5247 had the strongest activity of all drugs tested against streptococci (except Streptococcus faecalis) and was as active as cefaclor and cefalexin against most strains of Staphylococcus aureus. Ro 19-5247 was the only oral cephalosporin active against Bordetella pertussis. It was on average 160 times more active than cefaclor against Haemophilus influenzae. In its activity against enterobacteria Ro 19-5247 was always superior to cefaclor and cefalexin. Only a few strains of Enterobacter aerogenes, Enterobacter cloacae, Klebsiella pneumoniae, Proteus vulgaris and Serratia marcescens were resistant to Ro 19-5247 as were all strains of Enterobacter agglomerans and Klebsiella ozaenae. Ro 15-8074 was inactive against staphylococci but ten times more active than cefaclor and cefalexin against Streptococcus pyogenes. There was no difference in the activity against Streptococcus pneumoniae and Streptococcus agalactiae. Against Haemophilus influenzae Ro 15-8074 acted 12 times stronger than cefaclor and 100 times stronger than cefalexin. The activity against enterobacteria corresponded to that of Ro 19-5247. Ro 15-8074 was also active against most strains of Enterobacter cloacae and Proteus vulgaris which were resistant to cefaclor and cefalexin.
...
PMID:In vitro activity of Ro 15-8074 and Ro 19-5247 in comparison to cefaclor and cefalexin. 359 8

Details of an enzyme immunoassay for the enumeration of antibody-forming cells are given with examples of its application to immunization with viral (Newcastle disease virus) or bacterial (Haemophilus pleuropneumoniae) pathogens of domesticated species. The assays showed reciprocal specificity when compared to another virus (avian paramyxovirus serotype 3) or another bacterium (Bordetella bronchiseptica) and were used to show the class specificity of avian AFC and the effect of passive antibody transfer on porcine AFC induction.
...
PMID:A rapid enzyme-linked semi-microwell assay for the enumeration of antibody-forming cells to viral and bacterial antigens in domestic animals. 361 97

Cefuzonam (L-105, CZON) was studied in pediatric infections. A summary of the results it as follows: For recently isolated Staphylococcus aureus strains, Peak MICs of CZON were distributed between 0.39 and 0.78 micrograms/ml showing a greater susceptibility of S. aureus to CZON than to cefoperazone (CPZ), latamoxef (LMOX), and cefmenoxime (CMX). Peak MICs of CZON for Escherichia coli were 0.10-0.20 micrograms/ml, similar to those of CPZ, LMOX, and CMX. Ampicillin (ABPC)-resistant strains were also susceptible to CZON. MICs for Salmonella were similar to those for E. coli. Peak MICs of CZON for Vibrio parahaemolyticus were 0.20-0.39 micrograms/ml. The susceptibility of the bacteria to CZON was far greater than to ABPC, and was similar to CPZ, LMOX, and CMX. With 20 mg/kg drip infusion, serum concentrations reached their peaks at the end of administration with values of 20.6-68.7 micrograms/ml, which decreased to 0.43-1.70 micrograms/ml after 2 hours. Half-lives of CZON in serum were 0.68-1.2 hours. With 50 mg/kg drip infusion, serum concentrations reached their peaks at the end of administration with levels of 69.0-82.0 micrograms/ml, and at after 2 hours 1.85-3.45 micrograms/ml. Thus, an apparent dose response was observed. Half-lives of CZON in serum were 0.63-0.99 hours. Urinary recovery rates in 6 hours were 39.9-80.5%. A total of 44 cases of 10 different types of acute pediatric infections was treated by CZON intravenous drip infusion as the main therapeutic procedure. The efficacy rate was 93.2%, and the compound was effective on purulent infections, acute urinary tract infection, etc. with pathogens such as ABPC-resistant S. aureus, E. coli, and Enterococcus faecalis. Dosage levels per day were 50 to 80 mg/kg in most cases. In infections with S. aureus (8 strains), Streptococcus pneumoniae (3 strains), E. faecalis (1 strain), Haemophilus parahaemolyticus (1 strain), Haemophilus parainfluenzae (2 strains), Haemophilus influenzae (11 strains), Bordetella pertussis (1 strain), E. coli (3 strains), a total of 30 strains, bacterial elimination was noted with an exception of 1 strain of S. aureus. The compound was used for 4 to 15 days, but side effects observed clinically were only 1 case of diarrhea and 1 case of thrombocytosis.
...
PMID:[Evaluation of cefuzonam in the pediatric field]. 361 82

The antibacterial effects of a combination of tiamulin and chlortetracycline in vitro against a number of field isolates of Pasteurella multocida, Haemophilus pleuropneumoniae and Bordetella bronchiseptica were examined. There was a marked synergism between the two antibiotics against all eight isolates of P multocida, against seven of nine isolates of H pleuropneumoniae and against the single strain of B bronchiseptica tested. Two field trials were carried out on a herd with a history of complicated enzootic pneumonia where the presence of Mycoplasma hyopneumoniae and P multocida had been established and subsequently the presence of H pleuropneumoniae was discovered. Feed containing tiamulin at 100 ppm combined with chlortetracycline at 300 ppm was given for seven days to pigs affected with pneumonia, and the results were compared with untreated controls and pigs receiving chlortetracycline at 300 ppm. There was a follow-up observation period of three weeks when all groups received unmedicated feed. During the medication period the combination treated groups showed a statistically significant increase in average daily weight gain of 156 g (20.4 per cent) and in feed conversion efficiency of 0.576 (20.8 per cent) and a numerical improvement in average disease score in comparison with the untreated controls. These improvements were approximately double those observed in the groups treated with 300 ppm chlortetracycline which showed improvements of 93 g (12.2 per cent) in average daily gain and 0.301 (10.9 per cent) in feed conversion efficiency. During the following three weeks most of the initial gains were lost, probably owing to the reinfection of the treated groups by the untreated controls.
...
PMID:The synergistic activity of tiamulin and chlortetracycline: in-feed treatment of bacterially complicated enzootic pneumonia in fattening pigs. 375 Jul 92

Antimicrobial agents were added to the feed of swine for three weeks to determine the interrelationships of potentially pathogenic agents in the nasal tract, turbinate atrophy and weight gains. Bordetella bronchiseptica was not isolated from the groups fed the combination of chlortetracycline, penicillin and sulfamethazine. B. bronchiseptica was found in some pigs after the feeding trail, but this organism was not significantly associated with turbinate atrophy at the time of slaughter.Mycoplasma hyorhinis was not found in the nasal passages of the pigs that received feed containing high concentration chlortetracycline but was found in pigs that received other diets. Hemophilus suis was not significantly reduced by any of the treatments used. The organisms studied in the pigs were not isolated from the personnel handling the pigs.
...
PMID:The effect of medicated feed on the nasal microflora and weight gain of pigs. 425 45

Endotoxin activity in suspensions of Bordetella pertussis, Escherichia coli, Haemophilus influenzae, and Pseudomonas aeruginosa was often markedly decreased by polymyxin B. Polymyxin B treatment may be a means to reduce inflammatory reactivity of lipopolysaccharide in vaccines of gram-negative bacteria.
...
PMID:Polymyxin B inactivation of lipopolysaccharide in vaccines of Gram-negative bacteria. 626 67

New restriction endonuclease has been isolated from Bordetella pertussis vaccine strain 305 and purified in 1 stage on Sepharose covalently bound with blue dextran. The isolated restrictase has been found capable of breaking down lambda-phag DNA into 7 fragments. According to its specificity, Bpe I is the isoschizomer of Hind III obtained from Haemophilus influenzae strain Rd.
...
PMID:[Isolation and purification of restriction endonuclease BpeI from Bordetella pertussis]. 628 68

Infections of the deeper respiratory airways can contribute to the progression of chronic asthmatic bronchitis. In the present report a number of microorganisms affecting the number of beta-adrenoceptors in guinea-pig lung homogenates are described. Haemophilus influenzae, Streptococcus pneumoniae, Bordetella pertussis and Escherichia coli O111B4 induced a significant decrease of the number of beta-adrenoceptors (by approximately 20%). Staphylococcus aureus, influenza A virus and Escherichia coli J5 were not active. These data point to a common factor shared by gram-negative bacilli; i.e. endotoxin. Purified endotoxin of E. coli O111B4 also decreased the number of beta-adrenoceptors, while E. coli J5-LPS did not. This suggests that neutral polysaccharides of bacterial cell walls, especially those in the 'O'-antigenic side chain of gram-negative endotoxins may be responsible for the decrease of beta-adrenoceptor number and therefore contribute to the pathogenesis of chronic asthmatic bronchitis. Intact endotoxin seems to be necessary since neither the isolated lipid nor the polysaccharide part of E. coli O111B4 LPS affected the number of beta-adrenoceptors in the lung.
...
PMID:Bacterial cell wall components decrease the number of guinea-pig lung beta-adrenoceptors. 630 48


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>